Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Former Bushveld subsidiary defaults on loan repayment

(Sharecast News) - Bushveld Minerals announced on Friday that Vanchem, a subsidiary it recently sold, has failed to repay ZAR 14.4m (£0.63m) plus accrued interest, which was due 21 November. The AIM-traded company said the payment was part of a shareholder loan owed to Bushveld Vanadium 2 (BV2), a group company and former shareholder of Vanchem.

It said the outstanding payment, which carries a 15% annual interest rate, was part of a broader loan balance due in December.

The repayment amount had already accounted for an offset of ZAR 35m related to kiln repairs and production losses incurred prior to the Vanchem sale.

However, Bushveld said it disputed the ZAR 35m estimate, and had agreed with the buyer, Southern Point Resources Fund I, to appoint an independent expert to verify the actual damages.

The final adjustment to the deferred consideration would depend on that assessment.

Bushveld said the funds, once recovered, were earmarked for partial repayment of an intercompany loan owed by BV2 to Bushveld Vametco Alloys.

Meanwhile, Bushveld said it had appointed business rescue practitioners for several South African subsidiaries, including Bushveld Vametco Alloys, Bushveld Vametco Holdings, and Bushveld Minerals SA.

The practitioners were engaging with Vanchem and exploring legal avenues to recover the overdue amount.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

Catenai extends convertible loan note facility with Klarian
(Sharecast News) - Digital media and technology specialist Catenai announced an extension to the redemption date of its £0.45m unsecured convertible loan note (CLN) facility with Klarian on Monday.
Eden Research revenue rises, losses set to widen
(Sharecast News) - Sustainable biopesticide and biocontrol technology specialist Eden Research reported significant revenue growth for the year ended 31 December on Monday, alongside a positive outlook for 2025.
Science Group set for another record adjusted operating profit
(Sharecast News) - Science Group said in an update on Monday that trading for the year ended 31 December was expected to deliver another record year of adjusted operating profit, in line with or slightly exceeding board expectations.
hVIVO completes pilot study for hMPV challenge model
(Sharecast News) - Contract research organisation and human challenge trial specialist hVIVO announced the successful completion of a pilot characterisation study for its human metapneumovirus (hMPV) challenge model on Monday.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.